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Abstract
Background: Reliable antenatal identification of pre-eclampsia and small for gestational age is crucial to judicious
allocation of monitoring resources and use of preventative treatment with the prospect of improving maternal/perinatal
outcome. The purpose of this systematic review was to determine the accuracy of five serum analytes used in Down's
serum screening for prediction of pre-eclampsia and/or small for gestational age.
Methods: The data sources included Medline, Embase, Cochrane library, Medion (inception to February 2007), hand
searching of relevant journals, reference list checking of included articles, contact with experts. Two reviewers
independently selected the articles in which the accuracy of an analyte used in Downs's serum screening before the 25th
gestational week was associated with the occurrence of pre-eclampsia and/or small for gestational age without language
restrictions. Two authors independently extracted data on study characteristics, quality and results.
Results: Five serum screening markers were evaluated. 44 studies, testing 169,637 pregnant women (4376 pre-eclampsia
cases) and 86 studies, testing 382,005 women (20,339 fetal growth restriction cases) met the selection criteria. The
results showed low predictive accuracy overall. For pre-eclampsia the best predictor was inhibin A>2.79MoM positive
likelihood ratio 19.52 (8.33,45.79) and negative likelihood ratio 0.30 (0.13,0.68) (single study). For small for gestational
age it was AFP>2.0MoM to predict birth weight < 10th centile with birth < 37 weeks positive likelihood ratio 27.96
(8.02,97.48) and negative likelihood ratio 0.78 (0.55,1.11) (single study). A potential clinical application using aspirin as a
treatment is given as an example.
There were methodological and reporting limitations in the included studies thus studies were heterogeneous giving
pooled results with wide confidence intervals.
Conclusion: Down's serum screening analytes have low predictive accuracy for pre-eclampsia and small for gestational
age. They may be a useful means of risk assessment or of use in prediction when combined with other tests.
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Background
Pre-eclampsia (PET) and small for gestational age (SGA)
remain significant causes of perinatal death and child-
hood disability [1-3]. PET has significant health implica-
tions for the mother with complications including adult
respiratory distress syndrome, coagulopathy, renal and
liver failure and stroke. Babies affected by SGA on reach-
ing adulthood are at greater risk of developing cardiovas-
cular disease, hypertension, and non-insulin dependent
diabetes [4,5]. Both PET and SGA are characterized by a
failure of the trophoblast invasion (at 16–22 weeks) into
the spiral arteries.
Second trimester serum screening for Down's syndrome is
routinely offered to women in the United Kingdom and
United States, either with the triple test (alpha-fetoprotein
(AFP), human chorionic gonadotrophin (HCG) and
unconjugated estriol) or with the addition of inhibin A as
the quadruple test. More recently first trimester screening
with fetal nuchal translucency, HCG and pregnancy asso-
ciated plasma protein A (PAPP-A) has provided an earlier,
more effective screening method [6]. Due to their origin
and sites of metabolism these biochemical markers may
be useful in the prediction of PET and SGA, there are how-
ever conflicting reports in the literature. Maternal serum
levels of these analytes have been shown to be associated
with adverse outcome [7,8] with low levels of PAPP-A
having been suggested as a marker for impaired placental
function and placentation [9]. There are studies however
reporting contrasting views [10].
Reliable antenatal identification of PET and SGA is crucial
to judicious allocation of monitoring resources and use of
preventative treatment [11] with the prospect of improv-
ing maternal and perinatal outcome. The variation in the
design of research on accuracy of tests for prediction of
PET and SGA, the scatter of this research across many data-
bases and languages, and the dearth of clear collated up-
to-date summaries of this literature contribute to the
uncertainty about the best screening and monitoring strat-
egies [12]. Systematic reviews of the literature can
improve our ability to identify those pregnancies at
increased risk of developing PET and SGA making addi-
tional use of test results already obtained for Down syn-
drome screening.
The purpose of our review was to investigate the accuracy
of serum biochemical markers used in first and second tri-
mester Down syndrome serum screening in predicting
PET and/or SGA. We systematically reviewed the available
literature and meta-analysed the data.
Methods
The systematic review was based on our previously pub-
lished prospective protocols [13,14] designed using
widely recommended methods [15-18]. The protocols are
available as Additional files 1 and 2.
Data sources and searches
Electronic searches were performed by experienced clini-
cal librarians targeting the prediction of PET and SGA. We
searched Medline, Embase, the Cochrane Library
(2006;4) and Medion from inception until February
2007. The search strategies are detailed in the published
protocols [13,14] and in Additional file 3. The reference
lists of all included primary and review articles were exam-
ined to identify cited articles not captured by electronic
searches. No language restrictions were applied.
Study selection
The first stage of study selection was the scrutinizing of the
database by two reviewers to identify articles from title
and/or abstract. In a second stage, a search based on key-
words for each of the analytes under review was per-
formed within the Reference Manager database. The
results of this search were scrutinized by a second
reviewer. In the final stage of study selection the full
papers of identified articles were obtained with final
inclusion or exclusion decisions made after independent
and duplicate examination of the papers. We included
studies that reported on singleton pregnancies at any level
of risk in any healthcare setting using any serum biochem-
ical test used in Down syndrome serum screening before
the 25th week of gestation. Test accuracy studies allowing
generation of 2 × 2 tables were included.
Data extraction and Study Quality Assessment
Further details on inclusion and exclusion criteria and
extracted clinical, methodological and statistical data can
be found in the published protocols.
Acceptable reference standards for PET were: persistent
systolic blood pressure (SBP) ≥ 140 mmHg or diastolic
blood pressure (DBP) ≥ 90 mmHg with proteinuria ≥ 0.3
g/24 hours or ≥ 1+ dipstick (= 30 mg/dl in a single urine
sample), new after 20 weeks of gestation. Severe PET was
defined as SBP ≥ 160 mmHg or DBP ≥ 110 mmHg with
proteinuria ≥ 2.0 g/24 hours or ≥ 3+ dipstick, or of early
onset < 34 weeks gestation. Superimposed PET was
defined as the development of proteinuria ≥ 0.3 g/24
hours or ≥ 1+ dipstick after 20 weeks gestation in chroni-
cally hypertensive patients [19]. Acceptable reference
standards for SGA included birth weight < 10th centile
adjusted for gestational age and based on local popula-
tion values and absolute birth weight threshold < 2500 g.
Severe SGA was defined as birth weight < 5th or < 3rd cen-
tile or < 1750 g or and preterm SGA for SGA leading to
delivery < 37 weeks. Neonatal ponderal index < 10th cen-
tile, skin fold thickness, and mid-arm circumference/head
circumference were also assessed [20-24].BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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Disagreements were resolved by consensus or arbitration
of a third reviewer. For multiple/duplicate publication of
the same data set, the most recent and/or complete study
was included only.
All included manuscripts were assessed by at least one
reviewer for study and reporting quality using validated
tools [25-30]. Methodological quality was defined as the
confidence that the study design, conduct and analysis
have minimized biases in addressing the research ques-
tion, thereby focusing on the internal validity (i.e. the
degree to which the results of an observation are correct
for the patients being studied). Items considered impor-
tant for a good quality paper were prospective design with
consecutive recruitment, full verification of the test result
with reference standard (> 90%), adequate description of
the index test and use of appropriate reference standard,
and application of any preventative treatments. Addi-
tional quality items were assessed for SGA papers;
whether they excluded cases of PET from the results,
whether fetuses with chromosomal and structural anom-
alies were excluded and whether stillbirths and intrauter-
ine deaths were excluded from the results. Further
explanation of the quality assessment can be found in
Additional file 4.
We excluded from the statistical analysis any paper with a
case-control design as this type of design in diagnostic test
accuracy studies has been shown to be associated with
bias and over/under estimation of accuracy [29].
Data synthesis and Analysis
From the 2 × 2 tables the following were calculated with
their 95% confidence intervals for individual studies; sen-
sitivity (true positive rate), specificity (true negative rate)
and the likelihood ratios (LR, the ratio of the probability
of the specific test result in people who do have the dis-
ease to the probability in people who do not). LRs indi-
cate by how much a given test result raises or lowers the
probability of having the disease and have been recom-
mended by Evidence-based Medicine Groups [31,32].
Results were pooled among groups of studies with similar
characteristics, the same threshold for the index test (PET
and SGA), same reference standard threshold for (SGA)
and the same trimester for testing. Where 2 × 2 tables con-
tained zero cells, 0.5 was added to each cell to enable cal-
culations.
Sub-groups were defined at the start of the review based
on clinical criteria known to affect prognosis, method of
index test or study quality: level of risk of population
(high or low based on authors assessment and calculated
incidence rates from results); type of assay used for index
test; whether babies with chromosomal anomalies were
excluded from the results; use of preventative treatment;
quality of study. Sub-group analyses were performed
where there were at least 3 studies with similar character-
istics within that group.
Heterogeneity was assessed graphically by looking at the
distribution of the sensitivities and specificities in the
receiver operating characteristic (ROC) space and LRs as a
measurement of accuracy size using a Forest plot. The log-
likelihood and X2 test were used to assess for heterogene-
ity statistically. When X2 p value > 0.05 (homogenous
data) the fixed effect pooling method was used; where
there was heterogeneity random effects pooling was used.
Summary ROC plots were produced (data not shown).
Sensitivity analysis was performed to check the robustness
of our results. A p value of < 0.05 was used throughout for
statistical significance.
All statistical analyses were performed using Meta-Disc
software http://www.hrc.es/investigacion/metadisc.html
and Statsdirect for drawing the Forest plots.
Clinical application
The clinical impact of estimates of accuracy for a screening
test depend on how the results of the test alter the
patient's pre-test probability of disease, based on disease
prevalence. The post-test probability can then be com-
bined with estimates of effectiveness for known treat-
ments [33]. From this data we can then calculate the
number of women needed to be tested (number needed
to test- NNTest), using a particular serum marker, to pre-
vent one case of SGA with a particular treatment and the
number needed to treat (NNTreat), the number of test
positive women needed to be treated to prevent one case
of SGA. In this review clinical application will be assessed
using aspirin as this is the only treatment with any level of
effectiveness for PET and SGA [11,34].
Results
Literature identification, study characteristics, and quality
Figure 1 summarises the process of literature identifica-
tion and selection. Tables detailing the individual study
characteristics of the included studies are available in
Additional file 5. There were twenty studies that reported
on both PET and SGA.
Pre-eclampsia
There were 44 included studies for pre-eclampsia [7,9,35-
75] reporting on 169,637 women (4376 preeclamptic
women, incidence 2.6%). Among these 44 studies, there
were 35 cohort studies and nine case-control studies
[41,43,44,48,51,55,63,72,73]. There were nine prospec-
tive studies, 10 retrospective and 25 were unclearly
designed. Calculated incidence rates of PET ranged from
0.6–44%. Incidence rates of PET correlated poorly with
descriptions of "high" or "low" risk study populations.BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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Process from initial search to final inclusion for biochemical screening to predict pre-eclampsia/small for gestational age (up to  February 2007) Figure 1
Process from initial search to final inclusion for biochemical screening to predict pre-eclampsia/small for ges-
tational age (up to February 2007). PET preeclampsia; PIH pregnancy induced hypertension; SGA small for gestational age.BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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Four of the studies were in "high-risk" populations (one
in IVF patients, one in patients with abnormal uterine
artery Doppler and two in patients with chronic hyperten-
sion) and in three of these studies the incidence of PET
was > 4%. However in 15 of the "low-risk" studies the
incidence was > 4% and in one study in which the inclu-
sion criteria were unclearly reported. The remaining 25
studies were in low risk, screening populations with a cal-
culated incidence of PET < 4%.
Ten studies were performed in the first trimester, 32 stud-
ies at a mean gestation between 15 to 20 weeks and two
studies 20 to 24 weeks.
The quality assessment of included studies for PET is sum-
marized in Figure 2. There was poor reporting of patient
selection criteria, description of index and reference tests
and blinding of the reference test. Only two studies
reported clearly whether preventative treatment had been
used. The nine case control studies were excluded from
the final meta-analysis, leaving 35 cohort studies for anal-
ysis.
Small for gestational age
There were 86 included studies for SGA
[7,9,37,39,47,51,53-55,57,59-61,64-67,69,74,76-141],
reporting on 382,005 women (20339 cases of SGA, inci-
dence 5.32%). Among these studies, there were 61 cohort
studies and 25 case control studies [53,55,76,77,82-
85,88,89,94,96,97,104,113,116,119,123-
125,130,131,133,135,140]. Thirty-one studies were pro-
spective, 17 retrospective and 38 of unclear design. Calcu-
lated incidence rates of SGA correlated well with the
threshold used in 78 of studies and poorly in 8, incidence
range for birth weight < 10th centile was 1.2–63%. Three
of the studies were performed in high risk populations,
whereas the remainder were performed in low risk or
screening populations. Due to the inclusion criteria of the
studies the majority of tests were performed between 15 to
20 weeks. There were ten studies reporting on first trimes-
ter screening. Fifty studies reported on birth weight < 10th
centile, 13 on birth weight < 5th centile, 27 on birth weight
< 2500 g, 1 on birth weight < 1500 g, 1 on birth weight <
15th centile and 12 reported no threshold.
The quality assessment of included studies for SGA
revealed deficiencies (Figure 2). Only 40 studies con-
tained an adequate description of the performance of the
index test. None of the studies reported clearly on the per-
formance of the reference standard. Blinding of the refer-
ence test was also poorly reported as was the use of any
treatment in between the index test and reference stand-
ard. These items of quality of study design are important
in diagnostic accuracy reviews.
Four papers only distinguished between SGA with PET
and SGA alone; intrauterine deaths and stillbirths were
excluded from the results for SGA in only 16 papers, in the
remainder it was unclear; chromosomal and structural
anomalies were excluded from 62 studies, unclear in 24
Twenty-five case control studies and eight studies
[78,81,98,105,122,127,129,138] in which thresholds for
SGA were not defined were excluded from the final meta-
analysis, leaving 53 studies.
Data analysis
For both analysis for PET and analysis for SGA, there was
significant heterogeneity in all results. As a consequence
of this the random effects model was used throughout the
study.
Maternal serum alpha fetoprotein (AFP)
The results for AFP are summarized in Figure 3, all studies
were performed in the second trimester. For PET there
were sixteen studies included in the meta-analysis.
Thresholds that were most commonly used were >
2.0MoM (multiples of median) (10 studies) and >
2.5MoM (6 studies). The most accurate predictor was
AFP>2.0 MoM; LR+ 2.36 (1.46,3.83), LR- 0.96
(0.95,0.98). (One study had a better positive LR however
this threshold was chosen from receiver operating curve
analysis AFP>1.28MoM; LR+ 3.30 (2.00,5.43), LR-
0.44(0.22,0.90)).
For SGA there were thirty studies included in the meta-
analysis. The commonest threshold used were > 2.0MoM
(10 studies) and > 2.5MoM (5 studies) to predict birth
weight < 10th centile. The best predictor for birth weight <
10th centile was AFP<10th centile; LR+ 8.80 (5.57,13.91),
LR- 0.02 (0.00,0.34), this was a single study. For birth
weight < 5th  centile and birth weight < 2500 g,
AFP>3.0MoM was the most accurate predictor. The most
accurate predictor overall was AFP>2.0MoM to predict
severe SGA (birth weight < 10th centile with birth < 37
weeks): LR+ 27.96 (8.02,97.48), LR- 0.78 (0.55, 1.11).
Maternal serum human chorionic gonadotrophin (HCG)
The results for HCG are summarized in Figure 4. There
were forty seven studies overall evaluating HCG, nine for
free β-HCG, eight total β-HCG and 30 total HCG. For PET
there were 21 included studies in the meta-analysis, 3
looked at testing in the first trimester. The commonest
thresholds used were HCG>2.0MoM (12 studies),
HCG>2.5MoM (4 studies) and HCG>3.0MoM (3 stud-
ies). The most accurate predictor was HCG>2.0MoM with
second trimester testing; LR+ 2.45 (1.57,3.84), LR- 0.89
(0.83,0.96). There was one study looking at severe PET as
the outcome, results showed no improvement in predic-
tion.BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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Bar chart showing quality of evidence on biochemical screening markers to predict small for gestational age and pre-eclampsia Figure 2
Bar chart showing quality of evidence on biochemical screening markers to predict small for gestational age 
and pre-eclampsia.
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For SGA there were 22 included studies in the meta-anal-
ysis, 5 looked at testing in the first trimester. The com-
monest thresholds used were HCG>2.0MoM (7 studies)
and HCG>2.5MoM (4 studies) for birth weight < 10th cen-
tile. The most accurate predictor for birth weight < 10th
centile was HCG>2.0MoM; LR+ 1.74 (1.48,2.04), LR-
0.95 (0.93,0.96). For birth weight < 5th  centile
HCG>2.0MoM in the second trimester was the most accu-
rate and for birth weight < 2500 g HCG>2.5MoM.
Maternal serum unconjugated Estriol
The results for unconjugated estriol are summarized in
Figure 5, all studies were performed in the second trimes-
ter. For PET there were 4 included studies, the commonest
threshold being estriol<0.5MoM (2 studies), this was also
the most accurate predictor; LR+ 1.50 (1.02,2.19), LR-
0.99 (0.97,1.00).
For SGA there were 7 included studies, the commonest
threshold was estriol<0.75MoM (2 studies) for birth
weight < 10th centile. The most accurate predictor for birth
weight < 10th  centile was estriol<0.75MoM; LR+ 2.54
(1.54,4.19), LR- 0.75 (0.63,0.89). For birth weight < 5th
centile there were 2 studies for estriol<0.5 MoM; LR+ 6.54
(0.98,43.91), LR- 0.59 (0.03,13.28).
Maternal serum pregnancy associated plasma protein A 
(PAPP-A)
The results for PAPP-A are summarized in Figure 6. For
PET there were 16 included studies, all performed in the
first trimester, the commonest threshold was PAPP-A<5th
centile (5 studies) and PAPP-A<10th centile (3 studies).
The most accurate predictor was PAPP-A<5th centile; LR+
2.10 (1.57,2.81), LR- 0.95 (0.93,0.98).
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of  alpha feto-protein (AFP) to predict pre-eclampsia and small for gestational age (birth weight threshold as indicated) Figure 3
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% 
CI) for studies of alpha feto-protein (AFP) to predict pre-eclampsia and small for gestational age (birth weight 
threshold as indicated). Results with diamonds are pooled results (number of studies as indicated), results with squares are 
single studies. The number of women included in the studies is shown, all studies second trimester testing.
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Birth weight <10th centile
1.18 (0.62, 2.26)
0.30 (0.07, 1.19)
1.01 (0.99, 1.02)
1.02 (0.98, 1.06)
3.30 (2.00, 5.43)
1.28 (1.14, 1.43)
1.35 (0.59, 3.12)
2.36 (1.46, 3.83)
2.35 (1.65, 3.36)
1.35 (0.08, 22.23)
Pre-eclampsia
Likelihood ratio of positive test
AFP>2.0MoM 1 7,307
Threshold No of studies No of women
AFP<0.44MoM 1 13,486
AFP>2.0MoM 3 23,694
AFP>2.5MoM 2 5,619
AFP>3.0MoM 2 4,424
AFP>90th centile 1 476
AFP>95th centile 1 220
Threshold No of studies No of women
AFP<0.44MoM 1 51,008
AFP>1.0MoM 2 52,747
AFP>1.5MoM 1 1,739
AFP>2.0MoM 4 101,597
AFP>2.5MoM 2 111,048
AFP>3.0MoM 1 15,705
Threshold No of studies No of women
AFP<10th centile 1 172
AFP>1.0MoM 1 1,739
AFP>1.5MoM 2 4,354
AFP>1.6MoM 1 358
AFP>1.7MoM 1 147
AFP>2.0MoM 10 45,158
AFP>2.5MoM 5 15,023
AFP>3.0MoM 1 333
AFP>90th centile 2 648
AFP>95th centile 1 828
Threshold No of studies No of women
AFP<0.4MoM 1 13,486
AFP<0.44MoM 1 51,008
AFP>0.58MoM 1 51,008
AFP>0.82MoM 1 51,008
AFP>1.28MoM 1 178
AFP>1.35MoM 1 51,008
AFP>1.5MoM 2 4,613
AFP>2.0MoM 10 103,627
AFP>2.5MoM 6 119,709
AFP>3.0MoM 1 1998
Threshold No of studies No of women
Index Test Study Details Likelihood ratio of positive test (95% CI)                         Likelihood ratio of negative test (95% CI)
0.78 (0.55, 1.11)
BW<10th centile, 37 weeks
0.99 (0.94, 1.04)
0.94 (0.89, 0.99)
0.88 (0.70, 1.11)
0.96 (0.94, 0.98)
0.92 (0.81, 1.05)
0.97 (0.87, 1.10)
Birth weight <2500g
0.99 (0.98, 0.99)
0.95 (0.74, 1.21)
0.92 (0.84, 1.01)
0.95 (0.92, 0.98)
0.98 (0.96, 0.99)
0.98 (0.96, 0.99)
Birth weight <5th centile
0.02 (0.00, 0.34)
0.81 (0.69, 0.95)
0.94 (0.90, 0.98)
0.92 (0.86, 0.99)
0.94 (0.75, 1.16)
0.96 (0.93, 0.98)
0.98 (0.91, 1.05)
0.78 (0.61, 0.98)
0.93 (0.85, 1.01)
1.00 (0.94, 1.07)
Birth weight <10th centile
0.99 (0.97, 1.02)
1.01 (1.00, 1.01)
0.95 (0.59, 1.23)
0.94 (0.82, 1.08)
0.44 (0.22, 0.90)
0.91 (0.86, 0.96)
0.96 (0.83, 1.11)
0.96 (0.95, 0.98)
0.98 (0.97, 0.99)
1.00 (0.97, 1.03)
Pre-eclampsia
0.01 0.1 0.2 0.5 1 2
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For SGA there were 10 included studies, 7 were performed
in the first trimester, the commonest thresholds were
PAPP-A < 5th centile (4 studies), PAPP-A<10th centile (5
studies) for birth weight < 10th centile. The most accurate
predictor for birth weight < 10th centile was PAPP-A<1st
centile; LR+ 3.50 (2.53,4.82), LR- 0.98 (0.97,0.99). For
birth weight < 5th centile, the most accurate predictor was
again PAPP-A<1st centile; LR+ 4.36 (3.27,5.80), LR- 0.97
(0.96,0.98).
Maternal serum inhibin A
The results for inhibin A are summarized in Figure 7. For
PET there were 6 included studies, 1 performed in the first
trimester, the commonest threshold being inhibin
A>2.0MoM (2 studies) with a LR+ 6.00 (5.12,7.03), LR-
0.72 (0.48,1.09). The most accurate predictor for PET was
inhibin A>2.79MoM; LR+ 19.52 (8.33,45.79), LR- 0.30
(0.13,0.68), however this result was derived from one
study using a receiver operating characteristic curve to
determine threshold.
For SGA there was only one study, looking at second tri-
mester testing, using a cut-off of inhibin A>2.0MoM, the
results for prediction of birth weight < 10th centile were
LR+ 4.45 (3.92,5.06), LR- 0.92 (0.91,0.93) and birth
weight < 5th  centile; LR+ 4.91 (4.20,5.73), LR- 0.89
(0.87,0.91).
Triple test (serum AFP, HCG and unconjugated estriol)
There were no included studies for PET. For SGA there
were 2 studies, second trimester testing, with different cut-
offs for prediction of birth weight < 10th centile: triple test
> 1:190 LR+ 1.07 (0.60,1.91), LR- 0.98 (0.82,1.17) and
triple test>1:250 LR+ 2.71 (1.77,4.17), LR- 1.19
(0.01,2.47).
Gestation of testing
Table 1 shows the different results achieved where testing
was performed in both the first and second trimester.
Overall for HCG, testing in the second trimester was more
accurate.
Sub-group and sensitivity analysis
For sub group analysis, a sub-group had to include at least
three studies within each analyte and threshold and thus
was only possible for calculated incidence of disease. The
results for sub-group analysis are shown in Table 2. There
was no significant difference between the subgroups.
Most of the studies included in the review excluded
fetuses with other structural or chromosomal anomalies
from the results and included live births only thus sub-
group analysis could not be performed in these areas. Sen-
sitivity analysis including only those studies with these
characteristics showed no significant difference. The same
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of  human chorionic gonadotrophin (HCG) to predict pre-eclampsia and small for gestational age (birth weight threshold as indi- cated) Figure 4
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% 
CI) for studies of human chorionic gonadotrophin (HCG) to predict pre-eclampsia and small for gestational 
age (birth weight threshold as indicated). Results with diamonds are pooled results (number of studies as indicated), 
results with squares are single studies. The number of women included in the studies is shown. (a first trimester testing).
0.01 0.1 0.2 0.5 1 2 5 10 100
1.78 (1.47, 2.16)
7.64 (2.86,20.46) Birth weight <2500g
1.61 (1.19, 2.17)
1.82 (1.27, 2.60)
0.98 (0.84, 1.14)
1.02 (0.79, 1.30)
2.08 (1.78,2,42)
1.26 (0.97, 1.65)
1.11 (0.48, 2.58)
0.28 (0.02, 4.53)
0.59 (0.04, 9.61)
Birth weight <5th centile
2.55 (1.21, 5.35)
1.31 (0.97, 1.77)
12.35 (0.80,6.92)
0.97 (0.88, 1.08)
1.29 (0.98, 1.70)
1.74 (1.48, 2.04)
1.49 (1.16, 1.90)
4.71 (1.22,18.17)
4.17 (2.65, 6.54)
1.68 (0.37, 7.63)
0.99 (0.64, 1.54)
1.02 (0.37, 2.78)
Birth weight <10thcentile
1.23 (0.80, 1.88)
0.93 (0.40, 2.15)
0.80 (0.20, 3.17)
0.39 (0.03, 6.30) Severe pre-eclampsia
1.58 (0.67, 3.70)
5.90 (1.07,32.62)
1.35 (1.06, 1.73)
1.72 (1.33, 2.22)
1.71 (1.14, 2.57)
1.23 (0.80, 1.88)
1.66 (0.96, 2.89)
3.35 (1.90, 5.89)
1.66 (0.76,3.65)
2.45 (1.57, 3.84)
3.34 (1.93, 5.77)
1.44 (1.18, 1.76)
2.30 (0.70, 7.63)
0.81 (0.06, 11.06)
Pre-eclampsia
Likelihood ratio of positive test
HCG>2.0MoM 2  1,557
HCG>2.5MoM 1   471
Threshold No of studies  No of women
HCG <5th centilea 2 1 4 , 1 3 6
HCG <10th centilea 15 , 2 9 7
HCG <mediana 15 , 2 9 7
HCG>1.0MoMa 11 , 6 2 2
HCG>2.0MoM 1 33,145
HCG>2.5MoM 1  45,565
HCG.3.0MoMa 11 , 6 2 2
HCG>4.0MoMa 11 , 6 2 2
HCG>5.0MoMa 11 , 6 2 2 Threshold  No of studies   No of women
HCG <1st centile a 16 , 2 7 6
HCG <5th centilea 2 1 1 , 5 7 3
HCG <10th centile 1 172
HCG <mediana 15 , 2 9 7
HCG>1.5MoM 1 2,615
HCG>2.0MoM 7  39,306
HCG>2.5MoM 4 9,913
HCG>3.0Mom 1 88
HCG>4.0MoM 1 121
HCG >90th centile 1 172
HCG >95th centilea 16 , 2 7 6
HCG >99th centilea 16 , 2 7 6 Threshold  No of studies   No of women
HCG>1.5MoM 1 1,998
HCG>2.0MoM 1 1,998
HCG>2.5MoM 1 1,998
HCG>3.0MoM 1 1,998 Threshold  No of studies   No of women
HCG <5th centilea 14 , 0 6 3
HCG <10th centilea 1 1 8 0
HCG>1.0MoM 1  430
HCG.1.17MoM 1  640
HCG>1.4MoM 1  640
HCG>1.5MoM 1 1,998
HCG>1.6MoM 1  640
HCG>1.75MoM 1  178
HCG>1.8MoM 1  430
HCG>2.0MoM 11  58,882
HCG>2.3MoM 1  640
HCG>2.5MoM 4  49,612
HCG>3.0MoM 3 8,224
HCG >90th centilea 1 1 8 0
Threshold  No of Studies No of women
0.60 (0.17, 2.07)
0.89 (0.85, 0.96)
Birth weight <2500g
0.97 (0.95, 0.99)
0.92 (0.86, 0.99)
1.02 (0.88, 1.19)
0.98 (0.71, 1.36)
0.94 (0.92, 0.95)
0.99 (0.98, 1.00)
0.99 (0.90, 1.09)
1.03 (1.00, 1.06)
1.01 (0.98, 1.04)
Birth weight <5thcentile
0.99 (0.97, 1.00)
0.99 (0.97, 1.00)
0.90 (0.76-1.00)
1.03 (0.93, 1.14)
0.95 (0.89, 1.01)
0.95 (0.93, 0.96)
0.95 (0.87, 1.03)
0.82 (0.66, 1.02)
0.13 (0.01, 1.77)
0.97 (0.86, 1.09)
1.00 (0.98, 1.03)
1.00 (0.99, 1.01)
Birth weight <10thcentile
0.93 (0.78, 1.12)
1.01 (0.92, 1.11)
1.01 (0.95, 1.07)
1.02 (0.99, 1.05)
Severe pre-eclampsia
0.76 (0.62, 0.92)
0.71 (0.32, 1.57)
0.51 (0.21, 1.22)
0.39 (0.16, 0.94)
0.64 (0.37, 1.08)
0.93 (0.78, 1.12)
0.78 (0.53, 1.14)
0.52 (0.28, 0.95)
0.78 (0.53, 1.14)
0.89 (0.83, 0.96)
0.76 (0.60, 0.95)
0.99 (0.95, 1.02)
0.97 (0.91, 1.04)
1.04 (0.71, 1.51)
Pre-eclampsia
0.01 0.1 0.2 0.5 1 2
Likelihood of a negative test
Index Test  Study Details Likelihood ratio of a positive test (95% CI) Likelihood ratio of a negative test (95% CI)BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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was true for the assessment of study quality i.e. most stud-
ies were of a similar quality to make sub-group analysis
impossible but sensitivity analysis showed no difference
when extremely low quality studies were excluded.
Forest plots of sensitivity and specificity are shown in
Additional file 6. Summary receiver operating characteris-
tic curves are available from the authors on request.
Clinical application with aspirin
The results for clinical application with aspirin for SGA are
shown in Table 3 and for PET in Table 4. The results show
that by testing with inhibin A for PET or SGA in a low risk
population we can reduce the number of women needed
to treat to prevent one case of SGA from 90 to 30 and for
PET from 323 to 27, having to test 909 and 469 women
respectively.
Discussion
We evaluated the accuracy of five serum screening markers
used in Down's syndrome screening. The results showed
low predictive accuracy overall. For PET the best predictor
was inhibin A>2.79MoM. However, it is important to
point out that this threshold was determined from a
receiver operating characteristic curve and based on a sin-
gle study. For SGA the best predictor overall for birth
weight < 10th  centile was AFP<10th  centile while
AFP>3.0MoM was the best predictor of birth weight < 5th
centile. These results were both based on single studies.
AFP and inhibin A showed improvements in predictive
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of  estriol to predict pre-eclampsia and small for gestational age (birth weight threshold as indicated) Figure 5
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% 
CI) for studies of estriol to predict pre-eclampsia and small for gestational age (birth weight threshold as indi-
cated). Results with diamonds are pooled results (number of studies as indicated), results with squares are single studies. The 
number of women included in the studies is shown, all studies second trimester testing.
0.01 0.1 0.2 0.5 1 2 5 10 100
Likelihood ratio of positive test
Threshold No of studies      No of women
Index Test Study Details Likelihood ratio of positive test (95% CI)                         Likelihood ratio of negative test (95% CI)
0.01 0.1 0.2 0.5 1 2
Likelihood ratio of a negative test
6.54 (0.98, 43.91)
Birth weight <5th centile
2.18 (1.68, 2.84)
3.07 (0.99, 9.51)
1.91 (1.13, 3.21)
2.54 (1.54, 4.19)
Birth weight <10th centile
1.50 (1.02, 2.19)
1.50 (0.73, 3.06)
1.45 (1.04, 2.02)
Pre-eclampsia
Estriol<0.5MoM               2                          57,649
Estriol<0.5MoM 1                         33,145
Estriol<0.7MoM 1                           547
Estriol<0.74MoM 1                           673
Estriol<0.75MoM 2                         1,405
Estriol<0.5MoM 2                         57,649
Estriol<0.75MoM 1                          309
Estriol<0.9MoM 1                        1,998
Threshold No of studies      No of women
Threshold No of studies      No of women
0.59 (0.03, 13.28)
Birth weight <5th centile
0.99 (0.98, 0.99)
0.96 (0.90, 1.02)
0.82 (0.65, 1.03)
0.75 (0.63, 0.89)
Birth weight <10th centile
0.99 (0.97, 1.00)
0.83 (0.54, 1.28)
0.81 (0.64, 1.04)
Pre-eclampsia
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Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of  pregnancy associated plasma protein A (PAPPA) to predict pre-eclampsia and small for gestational age (birth weight threshold  as indicated) Figure 6
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% 
CI) for studies of pregnancy associated plasma protein A (PAPPA) to predict pre-eclampsia and small for ges-
tational age (birth weight threshold as indicated). Results with diamonds are pooled results (number of studies as indi-
cated), results with squares are single studies. The number of women included in the studies is shown. (a first trimester testing).
0.01 0.1 0.2 0.5 1 2 5 10 100
Likelihoodratio of positive test
Threshold No of studies No of women
Index Test Study Details Likelihood ratio of positive test (95% CI)  Likelihood ratio of negative test (95% CI)
0.01 0.1 0.2 0.5 1 2
Likelihood ratio of a negative test
Pappa<1stcentilea 1 33,995
Pappa<5thcentilea 4 49,009
Pappa<10thcentilea 3 40,170
Pappa<mediana 1 5,297
Pappa<0.3MoMa 18 2 7
Pappa<0.4MoMa 14 7 6
Pappa<0.5MoMa 2 1,831
Pappa<0.69MoM a 14 7 6
Pappa<1stcentilea 2 40,271
Pappa<5thcentilea 4 46,446
Pappa<10thcentile 2 380
Pappa<mediana 1 5,297
Pappa>90thcentile 1 172
Pappa>95thcentilea 1 6,276
Pappa>99thcentilea 1 6,276
Pappa<0.25MoM a 1 1,622
Pappa<0.5MoMa 1 1,622
Pappa<0.75MoM a 1 1,622
Pappa<1.0MoMa 1 1,622
Pappa<1stcentilea 1 33,395
Pappa<5
thcentile
a 5 52,472
Pappa<10thcentilea 3 39,570
Pappa<mediana 15 2 9 7
4.36 (3.27, 5.80)
2.49 (2.20, 2.83)
2.24 (1.65, 3.03)
1.18 (1.03, 1.35)
Birth weight <5th centile
3.37 (1.44, 7.87)
2.51 (0.91, 6.95)
2.71 (1.91, 3.83)
2.04 (1.40, 2.98)
3.50 (2.53, 4.82)
2.09 (1.66, 2.63)
1.82 (0.95,3.50)
1.07 (0.96, 1.18)
0.91 (0.22, 3.65)
0.97 (0.61, 1.54)
1.00 (0.37, 2.77)
Birth weight <10thcentile
5.76 (2.22, 14.96)
1.50 (0.73, 3.06)
1.25 (0.79, 1.98)
1.06 (0.73, 1.52)
1.87 (1.12, 3.12)
2.10 (1.57, 2.81)
1.60 (1.12, 3.12)
1.22 (1.05, 1.40)
Pre-eclampsia
Threshold No of studies No of women
Threshold No of studies No of women
0.97 (0.96, 0.98)
0.92 (0.91, 0.94)
0.89 (0.84, 0.93)
0.84 (0.70, 0.99)
Birth weight <5th centile
0.92 (0.84, 1.01)
0.93 (0.82, 1.05)
0.83 (0.71, 0.96)
0.68 (0.49, 0.94)
0.98 (0.97, 0.99)
0.95 (0.93, 0.97)
0.91(0.79, 1.05)
0.94 (0.85, 1.04)
1.01 (0.85, 1.21)
1.00 (0.98, 1.02)
1.00 (0.99, 1.01)
Birth weight <10thcentile
0.87 (0.75, 1.02)
0.91 (0.75, 1.12)
0.88 (0.64, 1.20)
0.95 (0.64, 1.40)
0.99 (0.99, 1.00)
0.95 (0.93, 0.98)
0.94 (0.88, 1.00)
0.80 (0.65, 0.98)
Pre-eclampsia
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of  Inhibin A to predict pre-eclampsia and small for gestational age (birth weight threshold as indicated) Figure 7
Forest Plot showing likelihood ratio of a positive and negative test result with 95% confidence intervals (95% CI) for studies of 
Inhibin A to predict pre-eclampsia and small for gestational age (birth weight threshold as indicated). Results with diamonds are 
pooled results (number of studies as indicated), results with squares are single studies. The number of women included in the 
studies is shown. (a first trimester testing).
0.01 0.1 0.2 0.5 1 2 5 10 100
Likelihood ratio of positive test
Threshold No of studies No of women
Index Test Study Details Likelihood ratio of positive test (95% CI)   Likelihood ratio of negative test (95%CI)
0.01 0.1 0.2 0.5 1 2
Likelihoodratio of a negative test
InhibinA>2.0MoM 1 33,145
InhibinA>2.0MoM 1 33,145
Inhibin A>2.2MoM 1 640
Inhibin A>0.5MoM 1 640
Inhibin A>0.6MoM 1 640
Inhibin A>0.8MoM 1 640
Inhibin A>0.9MoM 1 640
Inhibin A>1.0MoM 1 640
Inhibin A>1.1MoM 1 640
Inhibin A>1.2MoM 1 640
Inhibin A>1.3MoM 1 640
Inhibin A>1.5MoM 1 640
Inhibin A>1.8MoM 1 58
InhibinA>2.0MoM 2 33,785
Inhibin A>2.2MoM 1 640
Inhibin A>2.5MoM 1 640
Inhibin A>2.79MoM 1 178
Inhibin A>3.0MoM 1 640
Inhibin A>mean+2sd 1 61
Inhibin A >95thcen tile a 17 5 9
4.91 (4.20, 5.73)
Birth weight <5thcentile
4.45 (3.92, 5.06)
Birth weight <10thcentile
11.57 (4.96, 27.03)
Severe Pre-eclampsia
1.09 (1.04, 1.14)
1.15 (1.05, 1.25)
1.35 (1.18, 1.54)
1.48 (1.25, 1.75)
1.72 (1.43, 2.08)
1.74 (1.36, 2.22)
1.82 (1.36, 2.45)
2.08 (1.52, 2.85)
2.61 (1.85, 3.67)
5.19 (1.51, 17.79)
6.00 (5.12, 7.03)
5.90 (3.57, 9.75)
6.24 (3.66, 10.66)
19.52 (8.33, 45.79)
7.56 (3.33, 17.18)
7.62 (1.78, 32.70)
7.14 (1.51, 19.01)
Pre-eclampsia
Threshold Noof studies No of women
Threshold No of studies No of women
Threshold No of studies No of women
0.89 (0.87, 0.91)
Birth weight <5thcentile
0.92 (0.91, 0.93)
Birth weight <10thcentile
0.69 (0.48, 0.98)
Severe Pre-eclampsia
0.14 (0.01, 2.28)
0.32 (0.08, 1.26)
0.33 (0.13, 0.84)
0.39 (0.19, 0.81)
0.37 (0.19, 0.73)
0.52 (0.32, 0.85)
0.60 (0.40, 0.90)
0.59 (0.40, 0.87)
0.58 (0.40, 0.83)
0.66 (0.45, 0.97)
0.72 (0.48, 1.09)
0.64 (0.49, 0.84)
0.67 (0.52, 0.86)
0.30 (0.13, 0.68)
0.82 (0.70, 0.97)
0.65 (0.46, 0.92)
0.70 (0.44, 1.11)
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accuracy when looking at severe disease for SGA and PET
respectively. HCG showed improved prediction when
comparing second trimester to first trimester testing.
The strength of our review and validity of its findings lies
in the methodological strengths used. We complied with
existing guidelines for the reporting of systematic reviews
[18] and also guidelines specific to the reporting of sys-
tematic reviews of observational studies [142]. We per-
formed extensive literature searches without language
restrictions. We paid careful attention to assessment of
quality of study design and reporting (The Quorum state-
ment for this review is shown in Additional file 7).
Previously published reviews in this area are restricted to
a systematic review evaluating predictive tests for PET
[143]. This review concluded that the tests investigated
had a low predictive value, the methodology of this review
has however been criticized [144] and was restricted in the
thresholds and tests it reviewed. To our knowledge there
are no previously reported systematic reviews in this area
for SGA.
We have primarily reported likelihood ratios in this
review as they are thought to be more clinically meaning-
ful than sensitivities and specificities, the use of likelihood
ratios allowing us to determine post test probabilities of
disease based on Bayes' theorem. Recent research suggests
that independently pooled likelihood ratios should be
interpreted with caution as positive and negative likeli-
hood ratios are related statistics (just like sensitivity and
specificity) [145]. We also pooled sensitivity and specifi-
Table 1: Subgroup analyses of accuracy of biochemical screening to predict small for gestational age and pre-eclampsia (random 
effects pooling).
Small for gestational age
Analyte Subgroup Positive Likelihood Ratio (95% CI) Negative Likelihood Ratio (95% CI) Sensitivity (95% CI) Specificity (95% CI)
HCG>90th centile (BW<10th centile)
Trimester
First 1.48 (0.57–3.81) 0.92 (0.72–1.17) 0.21 (0.06–0.46) 0.86 (0.79–0.91)
Second 1.68 (0.37–7.63) 0.97 (0.86–1.09) 0.08 (0.01–0.26) 0.95 (0.90–0.98)
HCG<10th centile (BW<10th centile)
Trimester
First 1.29 (0.05–33.56) 1.14 (0.53–2.43) 0.13 (0.10–0.16) 0.60 (0.57–0.63)
Second 2.35 (0.80–6.92) 0.90 (0.76–1.08) 0.16 (0.05–0.36) 0.93 (0.88–0.97)
HCG>2.0MoM (BW<5th centile)
Trimester
First 0.96 (0.55–1.68) 1.01 (0.88–1.17) 0.20 (0.10–0.34) 0.79 (0.77–0.81)
Second 2.08 (1.78–2.42) 0.94 (0.92–0.95) 0.12 (0.10–0.14) 0.94 (0.94–0.95)
PAPPA<10th centile (BW<10th centile)
Trimester
First 1.68 (1.25–2.27) 0.93 (0.88–0.98) 0.17 (0.16–0.19) 0.90 (0.89–0.90)
Second 1.82 (0.95–3.50) 0.91 (0.75–1.05) 0.20 (0.10–0.33) 0.89 (0.85–0.92)
Pre-eclampsia
HCG>2.0MoM
Trimester
First 1.77 (1.07–2.92) 0.80 (0.60–1.07) 0.37 (0.19–0.58) 0.79 (0.77–0.81)
Second 2.45 (1.57–3.84) 0.89 (0.83–0.96) 0.19 (0.17–0.21) 0.93 (0.93–0.93)
(CI confidence intervals, AFP alpha feto-protein, HCG human chorionic gonadotrophin, BW birth weight, MoM multiple of median). Analyses 
according to gestation of testing of accuracy of biochemical screening to predict small for gestational age and pre-eclampsia (random effects 
pooling). (CI confidence intervals, HCG human chorionic gonadotrophin, BW birth weight, MoM multiple of median, PAPPA pregnancy associated 
plasma protein A)BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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city and found no difference in the interpretation of the
results. Bivariate meta-analysis is a new statistical tech-
nique that explicitly incorporates the correlation between
sensitivity and specificity in a single model [146], its use
is however not yet widespread nor is it easily interpreted.
Our assessment of study quality was hindered by lack of
clear reporting, which is a common problem in diagnostic
reviews as standards for quality and checklists for assess-
ing it are fairly new. It has been previously reported that
poor study design and conduct can affect the estimates of
diagnostic accuracy [28,29] however, it is not entirely
clear how individual aspects of quality may effect this and
to what magnitude particularly in the area of Obstetrics.
Application of quality scores has been shown to be of little
value on diagnostic reviews [147] however, due to the lack
of clear reporting it was not possible to perform sub-group
analysis based on individual quality criteria.
One of the areas in which reporting was uniformly poor
was in the details provided regarding performance of the
reference standard. In PET definitions have changed over
time with previous definitions including change increases
in blood pressure. The measurement of blood pressure
was poorly reported. It is important to record diastolic
blood pressure with Korotkoff phase V as this is more reli-
ably recorded and reflects true diastolic blood pressure
[148-150]. For SGA there is still no convincing evidence as
to which is the best definition of the condition at birth nor
which is the best predictor of future infant and childhood
morbidity and mortality for term infants. Population
based birth weight standards were the most commonly
used, however it is important to realize that these do not
distinguish between the small healthy infant and the com-
promised infant. Customised growth charts that are
adjusted for sex, gestation, parity, maternal weight and
height and ethnicity, have been shown to improve the
detection of infants at risk of stillbirth [151] while neona-
tal indices have been shown to identify the malnourished
infant at risk of peripartum asphyxia [152]. Unfortunately
these were rarely used as outcome measures in the
included reviews.
Confounding factors in measurement of serum screening
markers but mainly AFP is its association with intrauterine
death, preterm labour and chromosomal and structural
anomalies [54,57,60]. Ideally all the included papers in
this review should have included only women with live
births and fetuses with no other chromosomal or struc-
tural anomalies, this however was not always clearly
Table 2: Subgroup analyses of accuracy of biochemical screening to predict small for gestational age and pre-eclampsia (random 
effects pooling)
Small for gestational age
Analyte Subgroup Positive Likelihood Ratio (95% CI) Negative Likelihood Ratio (95% CI) Sensitivity (95% CI) Specificity (95% CI)
AFP>2.0MoM (BW<10th centile)
Incidence
>10% 2.69 (1.36–5.31) 0.98 (0.96–1.00) 0.04 (0.02–0.08) 0.98 (0.98–0.99)
≤ 10% 3.71 (2.66–5.16) 0.93 (0.88–0.97) 0.06 (0.05–0.07) 0.98 (0.98–0.98)
HCG>2.0MoM(BW<10th centile)
Incidence
>10% 1.53 (1.1–2.12) 0.89 (0.77–1.04) 0.29 (0.22–0.37) 0.79 (0.77–0.82)
≤ 10% 1.92 (1.72–2.13) 0.95 (0.94–0.96) 0.11 (0.1–0.12) 0.94 (0.94–0.95)
Pre-eclampsia
AFP>2.0MoM
Incidence
>4% 0.85 (0.41–1.78) 1.01 (0.97–1.06) 0.06 (0.02–0.13) 0.93 (0.91–0.94)
≤ 4% 2.98 (1.77–5.03) 0.96 (0.95–0.97) 0.08 (0.06–0.09) 0.96 (0.96–0.96)
HCG>2.0MoM
Incidence
>4% 2.45 (0.65–2.93) 0.68 (0.42–1.1) 0.25 (0.21–0.3) 0.92 (0.91–0.93)
≤ 4% 2.36 (1.81–3.08) 0.89 (0.85–0.95) 0.18 (0.16–0.2) 0.93 (0.92–0.93)
(CI confidence intervals, AFP alpha feto-protein, HCG human chorionic gonadotrophin, BW birth weight, MoM multiple of median)BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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reported. Sensitivity analysis, including only studies that
did report exclusion of these subjects showed no signifi-
cant difference in estimates of test accuracy.
In this review we have also assumed that the markers act
independently but this may not be the case. The relation-
ship between PET and SGA must also be taken into
account. For HCG measurement the risk of SGA has been
shown by logistic regression to be dependent on the pres-
ence of PET [99]. Ideally included cases of SGA for this
review would have been those where there was no PET but
this was again poorly reported.
When assessing the clinical relevance of these tests it is
important to look at severe disease as this causes the
majority of maternal, fetal and neonatal complications
and thus prediction and prevention of this form of disease
would have the greatest health impact. For the studies
included in the meta-analysis there were only three that
had results for either severe PET or SGA and these were
insufficient to make an accurate assessment of the predic-
tion of this form of disease.
The calculations of NNTreat and NNTest show that we can
reduce the number of women needed to treat with aspirin
to prevent one case of SGA/PET if we first test with a serum
screening marker and then only treat the test positives. As
aspirin is not routinely used as a treatment these calcula-
tions serve to contextualize the predictive value of these
markers as individual tests. The costs of introducing aspi-
rin as a treatment would need to be balanced against the
costs of the test, costs of failing to treat the women with a
false negative result that then go on to develop disease
and any patient costs in terms of anxiety from screening
and over treatment in the false positive category. To thus
calculate the true clinical effectiveness of these tests these
results would need to be incorporated in to a full cost-
effectiveness analysis.
Table 3: Serum screening among pregnant women and number of women needed to be tested and treated with aspirin to prevent one 
case of SGA (birth weight < 10th centile).
Test result Prevalence SGA
(%)
Probability of SGA
after testing positive
(%)
Risk of SGA after 
treatment*
Probability of SGA 
after treatment
NNTest1 NNTreat2
No test, no 
treatment3
10.0 10.0 - 10.0 - -
No test, treat all3 10.0 - 0.90 9.0 - 90
Alpha feto-protein>2.0MoM: Sensitivity 60%; Specificity 98%
Test all, treat test 
positives
10.0 28.3 0.90 25.4 167 35
Human chorionic gonadotrophin>2.0MoM: Sensitivity 12%; Specificity 94%
Test all, treat test 
positives
10.0 16.2 0.90 14.6 833 62
Unconjugated estriol<0.75MoM: Sensitvity 37%; Specifcitiy 88%
Test all, treat test 
positives
10.0 22.0 0.90 19.8 270 45
Pregnancy associated plasma protein A (PAPP-A)<1st centile: Sensitivity 3%; Specificity 99%
Test all, treat test 
positives
10.0 28.0 0.90 25.2 3333 36
Inhibin A>2.0MoM: Sensitivity 11%; Specificity 98%.
Test all, treat test 
positives
10.0 33.1 0.90 29.8 909 30
Alpha feto-protein>2.0MoM to predict severe FGR: Sensitivity 22%, Specificity 99%
Test all, treat test 
positives
1.0 22.0 0.90 19.8 454 45
* RR 0.90 (95% CI 0.84–0.97) Askie et al. Antiplatelet agents for prevention of pre-eclampsia: meta-analysis of individual patient data. Lancet 
2007;369:1791–98;11.
1 NNTest is number needed to test and treat with aspirin to prevent one case of SGA calculated by 1/(proportion true positives (TP) – (proportion 
TP * RR)).
2 NNTreat is number need to treat if only treat test positives with aspirin calculated by 1/(probability after testing positive – probability after 
treatment).
3 Numbers are equal for all tests regardless of threshold, sensitivity and specificity.
MoM multiples of median
SGA small for gestational ageBMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
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As PET and SGA are diseases with relatively low prevalence
a clinically useful test would need to have a high positive
LR (> 10) and low negative LR (< 0.10) [153]. From the
results of this review it is unlikely that any one serum
screening marker in isolation will provide this. Future
research should thus concentrate in two areas. The first
should be to address the limitations within the primary lit-
erature as identified by this review; poor reporting, exclu-
sion of intrauterine deaths and chromosomal and
structural anomalies from the results, separation of PET
and SGA, prediction of severe disease. This may not neces-
sarily require further primary research as there are suffi-
cient large, well designed cohort studies available but
meta-analysis based on individual patient data. Secondly
future research should focus on combinations of markers
as predictors and combinations of tests such as serum
screening markers and uterine artery Doppler [154] to
improve the predictive accuracy to a clinically useful value.
As Down's serum screening is routinely performed in
many developed countries the cost of implementing use
of these results as a predictive test for PET and SGA would
be small. However as aspirin is the only preventative treat-
ment with any proven benefit in these conditions and has
minimal adverse events this cost has to be compared to
that of implementing aspirin treatment to all pregnant
women.
Conclusion
Down's serum screening analytes have low predictive
accuracy for pre-eclampsia and small for gestational age.
They may be a useful means of risk assessment or of use in
prediction when combined with other tests.
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Table 4: Serum screening among pregnant women and number of women needed to be tested and treated with aspirin to prevent one 
case of PET.
Test result Prevalence PET
(%)
Probability of PET
after testing positive
(%)
Risk of PET after 
treatment*
Probability of PET 
after treatment
NNTest1 NNTreat2
No test, no 
treatment3
3.0 3.0 - 3.0 - -
10.0 10.0 10.0
No test, treat all3 3.0 - 0.9 2.8 - 323
10.0 - 0.9 9.0 - 90
Alpha feto-protein>2.0MoM: Sensitivity 7%; Specificity 96%
Test all, treat test 
positives
3.0 7.3 0.9 6.1 4762 147
10.0 26.2 0.9 18.6 1429 48
Human chorionic gonadotrophin>2.0MoM, second trimester: Sensitivity 19%; Specificity 93%
Test all, treat test 
positives
3.0 7.5 0.9 6.3 1754 142
10.0 27.2 0.9 19.3 526 47
Unconjugated estriol<0.5MoM: Sensitvity 6%; Specifcitiy 96%
Test all, treat test 
positives
3.0 4.6 0.9 4.0 5556 226
10.0 16.7 0.9 12.8 1667 70
Pregnancy associated plasma protein A (PAPP-A)<5th centile: Sensitivity 9%; Specificity 95%
Test all, treat test 
positives
3.0 6.5 0.9 5.5 3704 167
10.0 23.3 0.9 17.0 1111 53
Inhibin A>2.79MoM: Sensitivity 71%; Specificity 96%.
Test all, treat test 
positives
3.0 6.0 0.9 3.4 469 27
10.0 216.9 0.9 61.2 141 15
* RR 0.90 (95% CI 0.81–1.01) Askie et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 
2007;369:1791–9811.
1 NNTest is number needed to test and treat with aspirin to prevent one case of FGR calculated by 1/(proportion true positives (TP) – (proportion 
TP * RR)).
2 NNTreat is number need to treat if only treat test positives with aspirin calculated by 1/(probability after testing positive – probability after 
treatment).
3 Numbers are equal for all tests regardless of threshold, sensitivity and specificity.
MoM multiples of median
PET pre-eclampsiaBMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
Page 15 of 19
(page number not for citation purposes)
Authors' contributions
The following authors were responsible for the study con-
cept and design: RKM, JSC, GtR, BWM, JAMvdP, JK, KSK,
SCR. The following authors were responsible for acquisi-
tion of data: RKM, JSC, ML, BWM.
Analysis and interpretation of data was performed by the
following authors: RKM, JSC, KSK. Drafting of the manu-
script was performed by: RKM, JSC, ML, GtR, BWM, JAM-
vdP, KSK, JK, SCR. Statistical analysis was performed by:
RKM, JSC, KSK. All authors read and approved the final
manuscript. 
RKM had full access to all of the data in the study and
takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Additional material
Acknowledgements
Faridi van Etten, Amsterdam Medical Center for help with searches. This 
study was supported by two project grants from Wellbeing of Women 
(NBTF626\03) and NHS Health Technology Assessment UK (01/64). The 
funding sources had no role in the collection, analysis, or interpretation of 
the data or in the decision to submit the manuscript for publication.
References
1. Hay WW Jr, Catz CS, Grave GD, Yaffe SJ: Workshop summary:
fetal growth: its regulation and disorders.  Pediatrics 1997,
99(6):585-591.
2. McIntire DJ, Bloom SL, Casey BM, Levenko KJ: Birth weight in rela-
tion to morbidity and mortality among newborn infants.  N
Eng J Med 1999, 340(16):1234-1238.
3. Taylor DJ, Howie PW: Fetal growth achievement and neurode-
velopmental disability.  Br J Obstet Gynaecol 1989, 96(7):789-794.
4. Rich-Edwards J, Colditz G, Stampfer M, Willett W, Gillman M, Hen-
nekens C: Birthweight and the risk for type 2 diabetes melli-
tus in adult women.  Ann Intern Med 1999, 130(4 Pt 1):278-284.
5. Barker DJ: The developmental origins of chromic adult dis-
ease.  Acta Paediatr Suppl 2004, 93(446):26-33.
6. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K: First
trimester screening for trisomies 21 and 18.  N Eng J Med 2003,
349(15):1405-1413.
7. Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, Johnson MP,
Evans MI: Second-trimester maternal serum marker screen-
ing: maternal serum alpha-fetoprotein, beta-human chori-
onic gonadotropin, estriol, and their various combinations as
predictors of pregnancy outcome.  Am J Obstet Gynecol 1999,
181(4):968-974.
8. Aquilina J, Maplethorpe R, Ellis P, Harrington K: Correlation
between second trimester maternal serum inhibin-A and
human chorionic gonadotrophin for the prediction of pre-
eclampsia.  Placenta 2000, 21(5–6):487-492.
9. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH: First tri-
mester maternal serum free beta human chorionic gonado-
trophin and pregnancy associated plasma protein A as
predictors of pregnancy complications.  BJOG 2000,
107(10):1265-1270.
10. Morssink LP, Kornman LH, Hallahan TW, Kloosterman MD, Beckhuis
JR, De Wolf BT, Montingh A: Maternal serum levels of free beta-
hCG and PAPP-A in the first trimester of pregnancy are not
associated with subsequent fetal growth retardation or pre-
term delivery.  Prenat Diagn 1998, 18(2):147-152.
11. Askie L, Duley L, Henderson-Smart D, Stewart L: Antiplatelet
agents for preventing pre-eclampsia: a meta-analysis of indi-
vidual patient data.  Lancet 2007, 369(9575):1791-1798.
12. Coomarasamy A, Frisk NM, Gee H, Robson SC: The Investigation
and Management of the Small for Gestational Age Fetus.  In
Guideline No 31 Nov 2002 RCOG, London; 2003. 
Additional file 1
"Prediction of pre-eclampsia: a protocol for systematic reviews of test accu-
racy." Study protocol for pre-eclampsia systematic reviews.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S1.pdf]
Additional file 2
"The value of predicting restriction of fetal growth and compromise of its 
wellbeing: Systematic quantitative overviews (meta-analysis) of test accu-
racy literature." Study protocol for fetal growth restriction systematic 
reviews.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S2.pdf]
Additional file 3
"Search strategies for biochemical markers used in Down's serum screen-
ing to predict preeclampsia/small for gestational age." Electronic search 
strategies for systematic reviews.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S3.doc]
Additional file 4
"Guide to QUADAS for Down's syndrome markers to predict pre-eclamp-
sia/small for gestational age." Guide to quality assessment of included 
papers in review using QUADAS tool.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S4.doc]
Additional file 5
"Study characteristics of studies of included studies for maternal serum 
biochemical (Down syndrome) screening to predict pre-eclampsia and 
small for gestational age."
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S5.doc]
Additional file 6
"Forest plots of sensitivity and specificity." Results of sensitivity and specif-
icity displayed as Forest plots.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S6.doc]
Additional file 7
"Improving the quality of reports of meta-analyses of randomised control-
led trials: the Quorum Statement checklist." The Quorum statement 
checklist.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2393-8-33-S7.bmp]BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
Page 16 of 19
(page number not for citation purposes)
13. Cnossen JS, Post JAM van der, Mol BW, Khan KS, Meads C, der Riet
G:  Prediction of pre-eclampsia: a protocol for systematic
reviews of test accuracy.  BMC Pregnancy and Childbirth 2006, 6:29.
14. Morris RK, Khan K, Coomarasamy A, Robson S, Kleijnen J: The
value of prediciting fetal growth restriction and compromise
of its wellbeing: Systematic quantitative overviews (meta-
analysis) of test accuracy literature.  BMC Pregnancy and Child-
birth 2007, 7:3.
15. Cochrane Methods Working Group on Systematic Reviews of
Screening and Diagnostic Tests: Recommended methods 1996.
16. Deeks J: Systematic reviews in health care: systematic
reviews of diagnostic and screening tests.  BMJ 2001,
323(7305):157-162.
17. Irwig L, Tosteson AN, Gatsonis C, Low J, Colditz G, Chalmers TC,
Mosteller F: Guidelines for meta-analyses evaluating diagnos-
tic tests.  Ann Intern Med 1994, 120(8):667-676.
18. Khan KS, Dinnes J, Kleijnen J: Systematic reviews to evaluate
diagnostic tests.  Eur J Obstet Gynecol Reprod Biol 2001, 95(1):6-11.
19. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM:
The classification and diagnosis of the hypertensive disorders
of pregnancy: statement from the International Society for
the Study of Hypertension in Pregnancy (ISSHP).  Hypertens
Pregnancy 2001, 20(1):IX-XIV.
20. McCowan LM, Harding JE, Stewart AW: Customized birthweight
centiles predict SGA pregnancies with perinatal morbidity.
BJOG 2005, 112(8):1026-1033.
21. Owen P, Farrell T, Hardwick JC, Khan KS: Relationship between
customised birthweight centiles and neonatal anthropomet-
ric features of growth restriction.  BJOG 2002, 109(6):658-662.
22. Fay RA, Dey PL, Saadie CM, Buhl JA, Gebski VJ: Ponderal index: a
better definition of the 'at risk' group with intrauterine
growth problems than birth-weight for gestational age in
term infants.  Aust N Z J Obstet Gynaecol 1991, 31(1):17-19.
23. Tamim H, Beydoun H, Itani M, Khogali M, Chokr I, Yunis KA, The
National Collaborative Perinatal Neonatal Network: Predicting
neonatal outcomes: birthweight, body mass index or pon-
deral index?  J Perinat Med 2004, 32(6):509-513.
24. Excler J, Sann L, Lasne Y, Picard J: Anthropometric assessment of
nutritional status in newborn infants. Discriminative value of
mid arm circumference and of skinfold thickness.  Early Hum
Dev 1985, 11(2):169-178.
25. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The
development of QUADAS: a tool for the quality assessment
of studies of diagnostic accuracy included in systematic
reviews.  BMC Med Res Methodol 2003, 3:25.
26. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kle-
ijnen J: Evaluation of QUADAS, a tool for the quality assess-
ment of diagnostic accuracy studies.  BMC Med Res Methodol
2006, 6:9.
27. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Orwig
LM, Lijmer JG, Moher D, Rennie D, de Vet HC, the STARD Group:
Towards complete and accurate reporting of studies of diag-
nostic accuracy: the STARD initiative.  BMJ 2003,
326(7379):41-44.
28. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Meulen JH
van der, Bossuyt PM: Empirical evidence of design-related bias
in studies of diagnostic tests.  JAMA 1999, 282(11):1061-1066.
29. Rutjes AW, Reitsma J, Di N, Smidt N, van Rijn J, Bossuyt PM: Evi-
dence of bias and variation in diagnostic accuracy studies.
CMAJ 2006, 174(4):469-476.
30. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J:
Development and validation of methods for assessing the
quality of diagnostic accuracy studies.  Health Technol Assess
2004, 8(25):iii, 1-234.
31. Honest H, Khan KS: Reporting of measures of accuracy in sys-
tematic reviews of diagnostic literature.  BMC Health Serv Resh
2002, 2(1):4.
32. Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical
literature. III. How to use an article about a diagnostic test.
B. What are the results and will they help me in caring for
my patients? The Evidence-Based Medicine Working Group.
JAMA 1994, 271(9):703-707.
33. Khan K, Chien PF: Seizure prophylaxis in hypertensive preg-
nancies: a framework for making clinical decisions.  Br J Obstet
Gynaecol 1997, 104(10):1173-1179.
34. Gulmezoglu M, de OM, Villar J: Effectiveness of interventions to
prevent or treat impaired fetal growth.  Obstet Gynecol Surv
1997, 52(2):139-149.
35. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F: The addi-
tion of activin A and inhibin A measurement to uterine
artery Doppler velocimetry to improve the early prediction
of pre-eclampsia.  Ultrasound Obstet Gynecol 2003, 21(2):165-169.
36. Zeeman GG, Alexander JM, McIntire DD, Byrd W, Leveno KJ:
Inhibin-A and superimposed preeclampsia in women with
chronic hypertension.  Obstet Gynecol 2003, 101(2):232-236.
37. Yaron Y, Ochshorn Y, Heifetz S, Lehavi O, Sapir Y, Orr-Urtreger A:
First trimester maternal serum free human chorionic gona-
dotropin as a predictor of adverse pregnancy outcome.  Fetal
Diagn Ther 2002, 17(6):352-356.
38. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A:
Decreased first trimester PAPP-A is a predictor of adverse
pregnancy outcome.  Prenat Diagn 2002, 22(9):778-782.
39. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Con-
nor JM: Early pregnancy levels of pregnancy-associated
plasma protein a and the risk of intrauterine growth restric-
tion, premature birth, preeclampsia, and stillbirth.  J Clin Endo-
crinol Metab 2002, 8((4)7):1762-1767.
40. Aquilina J, Thompson O, Thilaganathan B, Harrington K: Improved
early prediction of pre-eclampsia by combining second-tri-
mester maternal serum inhibin-A and uterine artery Dop-
pler.  Ultrasound Obstet Gynecol 2001, 17(16):477-484.
41. Lee LC, Sheu BC, Shau WY, Liu DM, Lai TJ, Lee YH, Huang SC: Mid-
trimester beta-hCG levels incorporated in a multifactorial
model for the prediction of severe pre-eclampsia.  Prenat
Diagn 2000, 20(9):738-743.
42. Leung TN, Chung TK, Madsen G, Lam CWK, Lam PKW, Walters
WAW, Smith R: Analysis of mid-trimester corticotrophin-
releasing hormone and alpha-fetoprotein concentrations for
predicting pre-eclampsia.  Hum Reprod 2000, 15(8):1813-1818.
43. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asse-
lin J, Ledger W, Groome N, Redman CWG: Serum inhibin A and
activin A are elevated prior to the onset of pre-eclampsia.
Hum Reprod 2000, 15(7):1640-1645.
44. Lambert-Messerlian GM, Silver HM, Petraglia F, Luisi S, Pelzani I, May-
bruck WM, Hogge WA, Hanley-Yanez K, Roberts JM: Second-tri-
mester levels of maternal serum human chorionic
gonadotropin and inhibin a as predictors of preeclampsia in
the third trimester of pregnancy.  J Soc Gynecol Investig 2000,
7(3):170-174.
45. Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH: Raised
maternal serum inhibin A concentration at 10 to 14 weeks of
gestation is associated with pre-eclampsia.  BJOG 2000,
107(6):795-797.
46. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA: Can
antenatal clinical and biochemical markers predict the
development of severe preeclampsia?  Am J Obstet Gynecol 2000,
182(3):589-594.
47. Haddad B, Abirached F, Louis-Sylvestre C, Le Blond J, Paniel BJ, Zorn
JR: Predictive value of early human chorionic gonadotrophin
serum profiles for fetal growth retardation.  Hum Reprod 1999,
14(11):2872-2875.
48. Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U: Predic-
tion of pre-eclampsia with maternal mid-trimester total
renin, inhibin A, AFP and free beta-hCG levels.  Prenat Diagn
1999, 19(2):122-127.
49. Pouta AM, Hartikainen AL, Vuolteenaho OJ, Ruokonen AO, Laatikai-
nen TJ: Midtrimester N-terminal proatrial natriuretic pep-
tide, free beta hCG, and alpha-fetoprotein  in predicting
preeclampsia.  Obstet Gynecol 1998, 91(6):940-944.
50. Luckas M, Hawe J, Meekins J, Neilson J, Walkinshaw S: Second tri-
mester serum free beta human chorionic gonadotrophin lev-
els as a predictor of pre-eclampsia.  Acta Obstet Gynecol Scand
1998, 77(4):381-384.
51. Onderoglu LS, Kabukcu A: Elevated second trimester human
chorionic gonadotropin level associated with adverse preg-
nancy outcome.  Int J Gynaecol Obstet 1997, 56(3):245-249.
52. Ashour AM, Lieberman ES, Haug LE, Repke JT: The value of ele-
vated second-trimester beta-human chorionic gonadotropin
in predicting development of preeclampsia.  Am J Obstet Gynecol
1997, 176(2):438-442.BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
Page 17 of 19
(page number not for citation purposes)
53. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S:
Maternal serum testing for alpha-fetoprotein and human
chorionic gonadotropin in high-risk pregnancies.  Prenat Diagn
1996, 16(12):1129-1135.
54. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB:
The association between maternal serum alpha-fetoprotein
and preterm birth, small for gestational age infants, preec-
lampsia, and placental complications.  Obstet Gynecol 1996,
88(5):816-822.
55. Heinonen S, Ryynanen M, Kirkinen P, Saarikoski S: Elevated midtri-
mester maternal serum hCG in chromosomally normal
pregnancies is associated with preeclampsia and velamen-
tous umbilical cord insertion.  Am J Perinatol 1996, 13(7):437-441.
56. Muller F, Savey L, Le Fiblec B, Bussieres L, Ndayizamba G, Colau JC,
Giraudet P: Maternal serum human chorionic gonadotropin
level at fifteen weeks is a predictor for preeclampsia.  Am J
Obstet Gynecol 1996, 175(1):37-40.
57. Wenstrom KD, Owen J, Davis RO, Brumfield CG: Prognostic sig-
nificance of unexplained elevated amniotic fluid alpha-feto-
protein.  Obstet Gynecol 1996, 87(2):213-216.
58. Vaillant P, David E, Constant I, Athmani B, Devulder G, Fievet P,
Gondry J, Boulanger JC, Fardelone P, Fournier A: Validity in nulli-
paras of increased beta-human chorionic gonadotrophin at
mid-term for predicting pregnancy-induced hypertension
complicated with proteinuria and intrauterine growth retar-
dation.  Nephron 1996, 72(4):557-563.
59. Simpson JL, Palomaki GE, Mercer B, Haddow JE, Andersen R, Sibai B,
Elias S: Associations between adverse perinatal outcome and
serially obtained second- and third-trimester maternal
serum alpha-fetoprotein measurements.  Am J Obstet Gynecol
1995, 173(6):1742-1748.
60. Milunsky A, Jick SS, Bruell CL, Maclaughlin DS, Tsung YK, Jick H, Roth-
man KJ, Willett W: Predictive values, relative risks, and overall
benefits of high and low maternal serum alpha-fetoprotein
screening in singleton pregnancies: new epidemiologic data.
Am J Obstet Gynecol 1989, 161(2):291-297.
61. Capeless EL, Kelleher PC, Walters CP: Elevated maternal serum
alpha-fetoprotein levels and maternal risk factors: Their
association with pregnancy complications.  J Reprod Med 1992,
37(3):257-260.
62. Morssink LP, Heringa MP, Beekhuis JR, De Wolf BT, Mantingh A: The
association between hypertensive disorders of pregnancy
and abnormal second-trimester maternal serum levels of
hCG and alpha-fetoprotein.  Obstet Gynecol 1997, 89(5 Pt
1):666-670.
63. Roes EM, Gaytant MA, Thomas CM, Raijmakers MTM, Zusterzeel
PLM, Peters WHM, Steegers EAP: First trimester inhibin-A con-
centrations and later development of preeclampsia.  Acta
Obstet Gynecol Scand 2004, 83(1):117.
64. Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R: Pre-
diction of preeclampsia or intrauterine growth restriction by
second trimester serum screening and uterine Doppler
velocimetry.  Fetal Diagn Ther 2005, 20(1):48-53.
65. Brajenovic-Milic B, Tislaric D, Zuvic-Butorac M, Back J, Petrovic O,
Ristic S, Mimica M, Kapovic M: Elevated second-trimester free
beta-hCG as an isolated finding and pregnancy outcomes.
Fetal Diagn Ther 2004, 19(6):483-487.
66. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH,
Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE,
Carr SR, Wolfe HM, Vidavar J, D'Alton ME: First-trimester mater-
nal serum PAPP-A and free-beta subunit human chorionic
gonadotropin concentrations and nuchal translucency are
associated with obstetric complications: a population-based
screening study (the FASTER Trial).  Am J Obstet Gynecol 2004,
191(4):1446-1451.
67. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA,
Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade
G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR,
Wolfe HM, D'Alton ME, FASTER Trial Research Consortium: Quad
screen as a predictor of adverse pregnancy outcome.  Obstet
Gynecol 2005, 106(2):260-267.
68. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T: Screening for pre-
eclampsia by using maternal serum inhibin A, activin A,
human chorionic gonadotropin, unconjugated estriol, and
alpha-fetoprotein levels and uterine artery Doppler in the
second trimester of pregnancy.  Aust N Z J Obstet Gynaecol 2005,
45(4):283-288.
69. Hershkovitz R, De SM, Kingdom J: Mid-trimester placentation
assessment in high-risk pregnancies using maternal serum
screening and uterine artery Doppler.  Hypertens Pregnancy
2005, 24(3):273-280.
70. Roiz-Hernandez J, de JC-M, Fernandez-Mejia M: Human chorionic
gonadotropin levels between 16 and 21 weeks of pregnancy
and prediction of pre-eclampsia.  Int J Gynaecol Obstet 2006,
92(2):101-105.
71. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH: Predic-
tion of pregnancy complications by first-trimester maternal
serum PAPP-A and free beta-hCG and with second-trimes-
ter uterine artery Doppler.  Prenat Diagn 2005, 25(10):949-953.
72. Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH:
Prediction of pre-eclampsia by uterine artery Doppler ultra-
sonography and maternal serum pregnancy-associated
plasma protein-A, free beta-human chorionic gonadotropin,
activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.
Ultrasound Obstet Gynecol 2006, 27(6):559-564.
73. Wald NJ, Morris JK, Ibison J, Wu T, George LM: Screening in early
pregnancy for pre-eclampsia using Down syndrome quadru-
ple test markers.  Prenat Diagn 2006, 26(6):559-564.
74. Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papantoniou N, Mesog-
itis S, Antsaklis A: Screening for pre-eclampsia and fetal growth
restriction by uterine artery Doppler and PAPP-A at 11–14
weeks' gestation.  Ultrasound Obstet Gynecol 2007, 29(2):135-140.
75. Kowalczyk TD, Cabaniss ML, Cusmano L: Association of low
unconjugated estriol in the second trimester and adverse
pregnancy outcome.  Obstet Gynecol 1998, 91(3):396-400.
76. Akinbiyi AA: Unexplained elevated maternal serum alpha-
fetoprotein in singleton pregnancies as a predictor of fetal
risk.  Int J Gynaecol Obstet 1996, 53(1):17-21.
77. Benn PA, Horne D, Briganti S, Rodis JF, Clive JM: Elevated second-
trimester maternal serum hCG alone or in combination
with elevated alpha-fetoprotein.  Obstet Gynecol 1996,
87(2):217-222.
78. Bernstein IM, Barth RA, Miller R, Capeless EL: Elevated maternal
serum alpha-fetoprotein: association with placental sonolu-
cencies, fetomaternal hemorrhage, vaginal bleeding, and
pregnancy outcome in the absence of fetal anomalies.  Obstet
Gynecol 1992, 79(1):71-74.
79. Bewley S, Chard T, Grudzinskas G, Cooper D, Campbell S: Early
prediction of uteroplacental complications of pregnancy
using Doppler ultrasound, placental function tests and com-
bination testing.  Ultrasound Obstet Gynecol 1992, 2(5):333-337.
80. Bloxam DL, Williams NR, Waskett RJ, Stewart SG: Disturbed zinc
metabolism and reduced birthweight related to raised
maternal serum alpha-fetoprotein in normal human preg-
nancies. [Review] [49 refs].  Acta Obstet Gynecol Scand 1994,
73(10):758-764.
81. Brazerol WF, Grover S, Donnenfeld AE: Unexplained elevated
maternal serum alpha-fetoprotein levels and perinatal out-
come in an urban clinic population.  Am J Obstet Gynecol 1994,
171(4):1030-1035.
82. Bremme K, Eneroth P, Nilsson B, Marsk L, Hagenfeldt L: Outcome
of pregnancy in relation to maternal serum alpha-fetopro-
tein levels in the second trimester. An evaluation of a screen-
ing program and a longitudinal follow-up.  Gynecol Obstet Invest
1988, 26(3):191-205.
83. Brock DJ, Barron L, Raab GM: The potential of mid-trimester
maternal plasma alpha-fetoprotein measurement in predict-
ing infants of low birth weight.  Br J Obstet Gynaecol 1980,
87(7):582-585.
84. Buckland CM, Thom H, Campbell AG: Maternal serum alpha-
fetoprotein levels in low birth weight singleton pregnancies.
J Perinat Med 1984, 12(3):127-132.
85. Burton BK: Outcome of pregnancy in patients with unex-
plained elevated or low levels of maternal serum alpha-feto-
protein.  Obstetrics & Gynecology 1988, 72(5):709-713.
86. Chapman SJ, Brumfield CG, Wenstrom KD, Dubard MB: Pregnancy
outcomes following false-positive multiple marker screening
tests.  Am J Perinatol 1997, 14(8):475-478.
87. Chard T, Rice A, Kitau MJ, Hird V, Grudzinskas JG, Nysenbaum AM:
Mid-trimester levels of alphafetoprotein in the screening of
low birthweight.  Br J Obstet Gynaecol 1986, 93(1):36-38.BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
Page 18 of 19
(page number not for citation purposes)
88. Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR, Summers AM:
Double-positive maternal serum screening results for down
syndrome and open neural tube defects: An indicator for
fetal structural or chromosomal abnormalities and adverse
obstetric outcomes.  Am J Obstet Gynecol 2002, 187(3):758-763.
89. Cho S, Durfee KK, Keel BA, Parks LH: Perinatal outcomes in a
prospective matched pair study of pregnancy and unex-
plained elevated or low AFP screening.  J Perinat Med 1997,
25(6):476-483.
90. Cox MU, Kingdom J, Whittle M, McNay M, Fleming J, Bowman A,
Crossley J, Aitken D: [Unexplained increase in maternal
plasma in alpha-fetoproteins in the second trimester of preg-
nancy: perinatal results].  Rev Chil Obstet Ginecol 1995,
60(3):174-180.
91. Cusick W, Rodis JF, Vintzileos AM, Albini SM, McMahon M, Campbell
WA:  Predicting pregnancy outcome from the degree of
maternal serum alpha-fetoprotein elevation.  J Reprod Med
1996, 41(5):327-332.
92. Di MM, Piazzi G, Ferrari A, Lotzniker M, Gerola O, Spinillo A: A
simultaneous evaluation of second trimester serum AFP,
hCG and unconjugated oestriol as predictors of small for
gestational age births.  Italian Journal of Gynaecology & Obstetrics
1998, 10(4):155-159.
93. Doran TA, Valentine GH, Wong PY, Wielgosz G, Benzie RJ, Soltan
HC, Jenner MR, Morland PA, Montogomery RJ, Allen LC: Maternal
serum alpha-fetoprotein screening: report of a Canadian
pilot project.  CMAJ 1987, 137(4):285-293.
94. Dungan JS, Shulman LP, Phillips OP, Simpson JL, Meyer NL, Greven-
good C, Elias S: Positive serum screening for fetal Down syn-
drome does not predict adverse pregnancy outcome in
absence of fetal aneuploidy.  J Soc Gynecol Investig 1994,
1(1):55-58.
95. Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E: Sec-
ond trimester total human chorionic gonadotropin, alpha-
fetoprotein and unconjugated estriol in predicting preg-
nancy complications other than fetal aneuploidy.  Eur J Obstet
Gynecol Reprod Biol 2003, 110(1):12-15.
96. Endres LK, Krotz S, Grobman WA: Isolated low second-trimes-
ter maternal serum beta-human chorionic gonadotropin is
not associated with adverse pregnancy outcome.  Am J Obstet
Gynecol 2003, 189(3):755-757.
97. Evans J, Stokes IM: Outcome of pregnancies associated with
raised serum and normal amniotic fluid alpha fetoprotein
concentrations.  Br Med J (Clin Res Ed) 1984, 288(6429):1494.
98. Ghosh A, Tang MH, Tai D, Nie G, Ma HK: Justification of maternal
serum alphafetoprotein screening in a population with low
incidence of neural tube defects.  Prenat Diagn 1986, 6(2):83-87.
99. Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M: The
association between unexplained second-trimester mater-
nal serum hCG elevation and pregnancy complications.
Obstet Gynecol 1992, 80(1):83-86.
100. Gordon YB, Lewis JD, Leighton M, Kitau MJ, Clarke PC, Chard T:
Maternal serum alpha-fetoprotein levels as an index of fetal
risk.  Am J Obstet Gynecol 1979, 133(4):422-424.
101. Haddow JE, Kloza EM, Smith DE, Knight GJ: Data from an alpha-
fetoprotein pilot screening program in Maine.  Obstet Gynecol
1983, 62(5):556-60.
102. Haddow JE, Knight GJ, Kloza EM, Palomaki GE: Alpha-fetoprotein,
vaginal bleeding and pregnancy risk.  Br J Obstet Gynaecol 1986,
93(6):589-593.
103. Haddow JE, Palomaki GE, Knight GJ: Can low birth weight after
elevated maternal serum alpha-fetoprotein be explained by
maternal weight?  Obstet Gynecol 1987, 70(1):26-28.
104. Hamilton MP, Abdalla HI, Whitfield CR: Significance of raised
maternal serum alpha-fetoprotein in singleton pregnancies
with normally formed fetuses.  Obstet Gynecol 1985,
65(4):465-470.
105. Hayashi M, Kohzu H: [Clinical studies on maternal serum
alpha-fetoprotein (MSAFP) of 532 cases – the median value,
pregnancy outcomes and clinical evaluation].  Nippon Sanka
Fujinka Gakkai Zasshi 1992, 44(10):1211-1218.
106. Heikkila A, Makkonen N, Heinonen S, Kirkinen P: Elevated mater-
nal serum hCG in the second trimester increases prematu-
rity rate and need for neonatal intensive care in primiparous
preeclamptic pregnancies.  Hypertens Pregnancy 2001,
20(1):99-106.
107. Heinonen S, Ryynanen M, Kirkinen P: The effects on fetal devel-
opment of high alpha-fetoprotein and maternal smoking.  Am
J Public Health 1999, 89(4):561-563.
108. Hershkovitz R, Erez O, Sheiner E, Landau D, Mankuta D, Mazor M:
Elevated maternal mid-trimester chorionic gonadotropin >
or = 4 MoM is associated with fetal cerebral blood flow redis-
tribution.  Acta Obstet Gynecol Scand 2003, 8((1)2):22-27.
109. Kavak ZN, Basgul A, Elter K, Uygur M, Gokaslan H: The efficacy of
first-trimester PAPP-A and free betahCG levels for predict-
ing adverse pregnancy outcome.  J Perinat Med 2006,
34(2):145-148.
110. Kim SY, Kim SK, Lee JS, Kim IK, Lee K: The prediction of adverse
pregnancy outcome using low unconjugated estriol in the
second trimester of pregnancy without risk of Down's syn-
drome.  Yonsei Med J 2000, 41(2):226-229.
111. Kiran TS, Bethel J, Bhal PS: Correlation of abnormal second tri-
mester maternal serum alpha-fetoprotein (MSAFP) levels
and adverse pregnancy outcome.  J Obstet Gynaecol 2005,
25(3):253-256.
112. Krantz D, Goetzl L, Simpson JL, Thom E, Zachery J, Hallahan TW, Sil-
ver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge
WA, Wilson RD, Mohide P, Hershey D, Wapner R, First Trimester
Maternal Serum Biochemistry and Fetal Nuchal Translucency Screen-
ing (BUN) Study Group: Association of extreme first-trimester
free human chorionic gonadotropin-beta, pregnancy-associ-
ated plasma protein A, and nuchal translucency with intrau-
terine growth restriction and other adverse pregnancy
outcomes.  Am J Obstet Gynecol 2004, 191(4):1452-1458.
113. Kuo PL, Lin CC, Lin YH, Guo HR: Placental sonolucency and
pregnancy outcome in women with elevated second trimes-
ter serum alpha-fetoprotein levels.  J Formos Med Assoc 2003,
102(5):319-325.
114. Kwik M, Morris J: Association between first trimester mater-
nal serum pregnancy associated plasma protein-A and
adverse pregnancy outcome.  Aust N Z J Obstet Gynaecol 2003,
43(6):438-442.
115. Legge M, Duff GB, Pike L, Aickin DR: Second trimester maternal
serum alpha-fetoprotein as an indicator of fetal risk.  Aust N Z
J Obstet Gynaecol 1985, 25(4):266-268.
116. Lepage N, Chitayat D, Kingdom J, Huang T: Association between
second-trimester isolated high maternal serum maternal
serum human chorionic gonadotropin levels and obstetric
complications in singleton and twin pregnancies.  Am J Obstet
Gynecol 2003, 188(5):1354-1359.
117. Lieppman RE, Williams MA, Cheng EY, Resta R, Zingheim R, Hickok
DE, Luthy DA: An association between elevated levels of
human chorionic gonadotropin in the midtrimester and
adverse pregnancy outcome.  Am J Obstet Gynecol 1993, 168(6 Pt
1):1852-1856.
118. Markestad T, Bergsjo P, Aakvaag A, Lie RT, Jacobsen G, Hoffman HJ,
Bakketeig LS: Prediction of fetal growth based on maternal
serum concentrations of human chorionic gonadotropin,
human placental lactogen and estriol.  Acta Obstet Gynecol Scand
Suppl 1997, 165:50-55.
119. Milunsky A, Nebiolo L: Maternal serum triple analyte screening
and adverse pregnancy outcome.  Fetal Diagn Ther 1996,
11(4):249-253.
120. Miyakoshi K, Tanaka M, Gabionza D, Ishimoto H, Miyazaki T,
Yoshimura Y: Prediction of smallness for gestational age by
maternal serum human chorionic gonadotropin levels and
by uterine artery Doppler study.  Fetal Diagn Ther 2001,
16(1):42-46.
121. Morssink LP, Kornman LH, Beekhuis JR, De Wolf BT, Mantingh A:
Abnormal levels of maternal serum human chorionic gona-
dotropin and alpha-fetoprotein in the second trimester: rela-
tion to fetal weight and preterm delivery.  Prenat Diagn 1995,
15(11):1041-1046.
122. Mwambingu FT: Association between unaccountably high
maternal alpha feto-protein and increased fetal risk.  Acta
Obstet Gynecol Scand 1985, 64(3):275-276.
123. Naylor CS, Porto M, Cohen B, Garite TJ: Pregnancy outcome in
Hispanic patients with unexplained positive triple marker
screening for Down syndrome.  J Matern Fetal Med 2001,
10(1):20-22.
124. Odibo AO, Sehdev HM, Stamilio DM, Macones GA: Evaluating the
thresholds of abnormal second trimester multiple markerPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pregnancy and Childbirth 2008, 8:33 http://www.biomedcentral.com/1471-2393/8/33
Page 19 of 19
(page number not for citation purposes)
screening tests associated with intra-uterine growth restric-
tion.  Am J Perinatol 2006, 23(6):363-7.
125. Ogle R, Jauniaux E, Pahal GS, Dell E, Sheldrake A, Rodeck C: Serum
screening for Down syndrome and adverse pregnancy out-
comes: a case-controlled study.  Prenat Diagn 2000, 20(2):96-99.
126. Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ: Adverse
pregnancy outcome after a false-positive screen for Down
syndrome using multiple markers.  Obstet Gynecol 1995,
86(2):255-258.
127. Roop AP, Boughman JA, Blitzer MG: Study of the relationship
between elevated maternal serum alpha-fetoprotein and
adverse pregnancy outcome.  Maryland Medical Journal 1991,
40(9):779-784.
128. Secher NJ, Eriksen PS, Hansen PK, Lenstrup C, Thisted J: High
maternal serum alpha-fetoprotein and low birthweight. A
study concerning possible correlation between maternal
weight, smoking, and serum alpha-fetoprotein and subse-
quent birthweight and gestational age.  Am J Perinatol 1985,
2(2):78-81.
129. Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, Cam-
eron AD, Connor MJ, Dobbie R: Pregnancy-associated plasma
protein A and alpha-fetoprotein and prediction of adverse
perinatal outcome.  Obstet Gynecol 2006, 107(1):161-6.
130. Sritippayawan S, Vachirasrisoontra C: Adverse pregnancy out-
comes after a false-positive second trimester serum screen
for Down syndrome in Thai pregnant women.  J Med Assoc Thai
2005, 88(4):449-454.
131. Summers AM, Huang T, Meier C, Wyatt PR: The implications of a
false positive second-trimester serum screen for Down syn-
drome.  Obstet Gynecol 2003, 101(6):1301-1306.
132. Tanaka M, Natori M, Ishimoto , Gohda N, Kiyokawa K, Yamauchi J,
Miyazaki T, Kpbayashi T, Nozawa S: [Screening for adverse peri-
natal outcome by biomarkers in maternal serum; a compar-
ison of elevated maternal serum alpha-fetoprotein versus
human chorionic gonadotropin].  Nippon Sanka Fujinka Gakkai
Zasshi 1994, 46(11):1229-1233.
133. Towner D, Gandhi S, El KD: Obstetric outcomes in women with
elevated maternal serum human chorionic gonadotropin.
Am J Obstet Gynecol 2006, 194(6):1676-81.
134. Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z: Predict-
ing complications of pregnancy with first-trimester maternal
serum free-betahCG, PAPP-A and inhibin-A.  Prenat Diagn
2003, 23(12):990-996.
135. Wald N, Cuckle H, Stirrat GM, Bennett MJ, Turnbull AC: Maternal
serum-alpha-fetoprotein and low birth-weight.  Lancet 1977,
2(8032):268-270.
136. Wald NJ, Cuckle HS, Boreham J, Turnbull AC: Maternal serum
alpha-fetoprotein and birth weight.  Br J Obstet Gynaecol 1980,
87(10):860-863.
137. Weiner CP, Grant SS, Williamson RA: Relationship between sec-
ond trimester maternal serum alpha-fetoprotein and umbil-
ical artery Doppler velocimetry and their association with
preterm delivery.  Am J Perinatol 1991, 8(4):263-268.
138. Wenstrom KD, Sipes SL, Williamson RA, Grant SS, Trawick DC, Estle
LC:  Prediction of pregnancy outcome with single versus
serial maternal serum alpha-fetoprotein tests.  Am J Obstet
Gynecol 1992, 167(6):1529-1533.
139. Westergaard JG, Teisner B, Hau J, Grudzinskas JG: Placental pro-
tein measurements in complicated pregnancies. I. Intrauter-
ine growth retardation.  Br J Obstet Gynaecol 1984,
91(12):1216-1223.
140. Williams MA, Hickok DE, Zingheim RW, Luthy DA, Kimelman J,
Nyberg DA, Mahon BS: Elevated maternal serum alpha-feto-
protein levels and midtrimester placental abnormalities in
relation to subsequent adverse pregnancy outcomes.  Am J
Obstet Gynecol 1992, 167(4 Pt 1):1032-1037.
141. Zarzour SJ, Gabert HA, Diket AL, St AM, Miller JM Jr: Abnormal
maternal serum alpha fetoprotein and pregnancy outcome.
J Matern Fetal Med 1998, 7(6):304-307.
142. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D,
Moher D, Beccker BJ, Sipe TA, Thacker SB: Meta-analysis of obser-
vational studies in epidemiology: a proposal for reporting.
Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) group.  JAMA 2000, 283(15):2008-2012.
143. Conde-Agudelo A, Villar J, Lindheimer M: World health organiza-
tion systematic review of screening tests for preeclampsia.
Obstet Gynecol 2004, 104(6):1367-1391.
144. Cnossen JC, Mol BW, Post JAM van der, Bossuyt PM, ter Riet G:
World health organization systematic review of screening
tests for pre-eclampsia.  Obstet Gynecol 2005, 105(5 Pt
1):1151-1152.
145. Zwinderman AH, Bossuyt PM: We should not pool diagnostic
likelihood ratios in systematic reviews.  Stat Med 2007 in press.
146. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinder-
man AH: Bivariate analysis of sensitivity and specificity pro-
duces informative summary measures in diagnostic reviews.
J Clin Epidemiol 2005, 58(10):982-990.
147. Whiting P, Harbord R, Kleijnen J: No role for quality scores in sys-
tematic reviews of diagnostic accuracy studies.  BMC Med Res
Methodol 2005, 5:19.
148. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, Peek
MJ, Rowan JA, Walters NJ: The detection, investigation and
management of hypertension in pregnancy: full consensus
statement.  Aust N Z J Obstet Gynaecol 2000, 40(2):139-155.
149. Shennan A, Gupta M, Halligan A, Taylor DJ, de Swiet M: Lack of
reproducibility in pregnancy of Korotkoff phase IV as meas-
ured by mercury sphygmomanometry.  Lancet 1996,
347(8995):139-142.
150. Brown MA, Reiter L, Smith B, Buddle ML, Morris R, Whitworth JA:
Measuring blood pressure in pregnant women: A compari-
son of direct and indirect methods.  Am J Obstet Gynecol 1994,
171(3):661-667.
151. Clausson B, Gardosi J, Francis A, Cnattingius S: Perinatal outcome
in SGA births defined by customised versus population based
birthweight standards.  BJOG 2001, 108(8):830-834.
152. Scott K, Usher R: Fetal malnutrition: its incidence, causes and
effects.  Am J Obstet Gynecol 1986, 94(7):951-963.
153. Deeks J, Altman D: Diagnostic tests: Likelihood ratios.  BMJ
2004, 329(7458):168-169.
154. Konchak PS, Bernstein IM, Capeless EL: Uterine artery Doppler
velocimetry in the detection of adverse obstetric outcomes
in women with unexplained elevated maternal serum alpha-
fetoprotein levels.  Am J Obstet Gynecol 1995, 173(4):1115-1119.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2393/8/33/prepub